Research programme: mRNA therapeutics - Alexion/Moderna Therapeutics

Drug Profile

Research programme: mRNA therapeutics - Alexion/Moderna Therapeutics

Alternative Names: ALXN 1540; ALXN 1630

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alexion Pharmaceuticals; Moderna Therapeutics
  • Class RNA
  • Mechanism of Action Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Crigler-Najjar syndrome

Most Recent Events

  • 27 Jul 2017 Alexion terminates its license agreement with Arbutus Biopharma for the latter's lipid nanoparticle (LNP) technology
  • 27 Jul 2017 Alexion terminates its R&D agreement with Moderna Therapeutics for the development of mRNA Therapeutics
  • 27 Jul 2017 Discontinued - Preclinical for Crigler-Najjar syndrome in USA (Parenteral) as a result of Alexion's redefined R&D strategy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top